Mu H, Lin KX, Zhao H, Xing S, Li C, Liu F, Lu HZ, Zhang Z, Sun YL, Yan XY, Cai JQ, Zhao XH. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J Gastroenterol 2014; 20(19): 5826-5838 [PMID: 24914343 DOI: 10.3748/wjg.v20.i19.5826]
Corresponding Author of This Article
Xiao-Hang Zhao, MD, PhD, State Key Laboratory of Molecular Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli 17, Chaoyang District, Beijing 100021, China. zhaoxh@cicams.ac.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 21, 2014; 20(19): 5826-5838 Published online May 21, 2014. doi: 10.3748/wjg.v20.i19.5826
Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry
Hong Mu, Kai-Xuan Lin, Hong Zhao, Shu Xing, Cong Li, Fang Liu, Hai-Zhen Lu, Ze Zhang, Yu-Lin Sun, Xi-Yun Yan, Jian-Qiang Cai, Xiao-Hang Zhao
Hong Mu, Fang Liu, Yu-Lin Sun, Xiao-Hang Zhao, State Key Laboratory of Molecular Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Kai-Xuan Lin, Ze Zhang, Xiao-Hang Zhao, Center of Basic Medical Sciences, Navy General Hospital of Chinese PLA, Beijing 100048, China
Hong Zhao, Cong Li, Jian-Qiang Cai, Department of Abdominal Surgery, Cancer Institute Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Hai-Zhen Lu, Department of Pathology, Cancer Institute Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Shu Xing, Xi-Yun Yan, Key Laboratory of Protein and Peptide Pharmaceutical, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
Author contributions: Mu H and Lin KX performed the majority of the work and wrote the manuscript; Zhao H, Li C, Liu F, Lu HZ, Zhang Z, and Sun YL assisted in the experiments and data analysis; Xing S analyzed the three dimensional reconstructions; Zhao XH, Yan XY, and Cai JQ supervised this work; Zhao XH designed the study.
Supported by Grants from the National High-tech R and D Program No. 2012AA020206, the Key Project for the Infectious Diseases No. 2012ZX10002-017 and No. 2013ZX10002009-001-004, the State Key Projects for Basic Research No. 2011CB910703, the National Natural Science Foundation No. 81372591, and No. 81321091 of China and the Center for Marine Medicine and Rescue of Tsinghua University
Correspondence to: Xiao-Hang Zhao, MD, PhD, State Key Laboratory of Molecular Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli 17, Chaoyang District, Beijing 100021, China. zhaoxh@cicams.ac.cn
Telephone: +86-10-67709015 Fax: +86-10-87778360
Received: December 31, 2013 Revised: February 14, 2014 Accepted: April 5, 2014 Published online: May 21, 2014 Processing time: 137 Days and 19.9 Hours
Core Tip
Core tip: We report a novel workflow to detect potentially valuable biomarkers for hepatocellular carcinoma (HCC). We measured immunofluorescence intensity and performed statistical analyses to assess the expression of biomarkers in cell lines and patient blood samples. Furthermore, we determined the expression of biomarkers via three-dimensional reconstructions. These analyses indicated that asialoglycoprotein receptor (ASGPR), glypican-3 (GPC3), and cytokeratin (CK) may be valuable HCC biomarkers for detecting circulating tumor cells (CTCs). In addition, the expression of ASGPR and GPC3 might correlate with patients’ prognoses, and our CTC detection method can include epithelial cell adhesion molecule- and vimentin-positive tumor cells, and will thus supplement previous studies and potentially help predict future tumor recurrence and metastasis.
